Pfizer, Inc.





Market Closed - Nyse 04:00:30 2024-06-14 pm EDT 5-day change 1st Jan Change
27.53 USD -0.43% Intraday chart for Pfizer, Inc. -3.67% -4.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FDA asks COVID vaccine makers to target KP.2 strain with updated shots RE
Pfizer: improved overall survival in myeloma CF
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years MT
Pfizer Inc. Announces Detailed Overall Survival Results from the Phase 2 MagnetisMM-3 Study of ELREXFIO CI
Health Care Flat on Mixed Drug Developments - Health Care Roundup DJ
Global markets live: Shell, Broadcom, Apple, Sony, Apple... Our Logo
Pfizer : share price down, Duchenne clinical trial failure CF
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Only one rate cut this year? Our Logo
Pfizer: presents results of treatment for DMD CF
Pfizer Prospective Treatment for Duchenne Muscular Dystrophy Fails to Meet Goals MT
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints DJ
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study RE
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says MT
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit MT
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation MT
GSK takes first steps to appeal Zantac ruling in Delaware AN
GSK: decisions in the Zantac (ranitidine) litigation CF
GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation MT
GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation RE
Latest trial over Zantac cancer claims called off as plaintiff drops case RE
GE Healthcare Technologies Inc. Announces Management Changes CI
Pfizer to Pause Sizable Acquisitions as it Integrates Existing Investments, CEO Says MT
Transcript : Pfizer Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 11:20 AM
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
27.53 USD
Average target price
31.92 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France